30/04/2024 – The Company will publish its annual financial report no later than May 15, 2024 Download PDF Post navigationPreviousPrevious post:AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSNextNext post:The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceRelated PostsPositive results of the Phase 2 study evaluating masitinib in Covid-19July 8, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024June 26, 2024 CGM – Q&A documentJune 26, 2024Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSMay 31, 2024AB Science webcast of May 30, 2024May 30, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSMay 29, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024
Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSMay 31, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSMay 29, 2024